{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:52:55Z","timestamp":1787788375997,"version":"build-2784847793"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Parents of children with developmental, behavioural and mental health disorders are increasingly asking whether medicinal cannabis might be a therapeutic option for their child. This paper presents the current evidence for medicinal cannabis in this population. Preliminary evidence from open-label studies suggests the potential for medicinal cannabis to ameliorate some symptoms in children with autism spectrum disorder. However, only one double-blind placebo-controlled trial has been completed, with inconclusive findings. Synthetic, transdermal cannabidiol gel has demonstrated efficacy for reducing social avoidance in a sub-group of children with Fragile X syndrome. Studies of medicinal cannabis are planned or underway for children and\/or adolescents with autism, intellectual disability, Tourette\u2019s syndrome, anxiety, psychosis, anorexia nervosa and a number of specific neurodevelopmental syndromes. High quality evidence from double-blind placebo-controlled trials is needed to guide clinical practice.<\/jats:p>","DOI":"10.3390\/ijerph20085430","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T04:08:03Z","timestamp":1680840483000},"page":"5430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Medicinal Cannabis for Paediatric Developmental, Behavioural and Mental Health Disorders"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-4496","authenticated-orcid":false,"given":"Daryl","family":"Efron","sequence":"first","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, 50 Flemington Rd, Parkville, VIC 3052, Australia"},{"name":"The Royal Children\u2019s Hospital, 50 Flemington Rd, Parkville, VIC 3052, Australia"},{"name":"Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Taylor","sequence":"additional","affiliation":[{"name":"Murdoch Children\u2019s Research Institute, 50 Flemington Rd, Parkville, VIC 3052, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jpc.13902","article-title":"Medical cannabis for paediatric developmental\u2013behavioural and psychiatric disorders","volume":"54","author":"Efron","year":"2018","journal-title":"J. Paediatr. Child Health"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"j3896","DOI":"10.1136\/bmj.j3896","article-title":"Psychotropic prescribing in people with intellectual disability and challenging behaviour","volume":"358","author":"Sheehan","year":"2017","journal-title":"BMJ"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.18773\/austprescr.2020.054","article-title":"The role of drugs in the treatment of autism","volume":"43","author":"Turner","year":"2020","journal-title":"Aust. Prescr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/jpc.13615","article-title":"Medication prescribed by Australian paediatricians: Psychotropics predominate","volume":"53","author":"Efron","year":"2017","journal-title":"J. Paediatr. Child Health"},{"key":"ref_5","first-page":"4","article-title":"Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice","volume":"25","author":"Garland","year":"2016","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.euroneuro.2009.04.008","article-title":"Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns","volume":"19","author":"Vitiello","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","article-title":"Endocannabinoid signaling in autism","volume":"12","author":"Chakrabarti","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.neuron.2013.02.036","article-title":"Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling","volume":"78","author":"Malenka","year":"2013","journal-title":"Neuron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41386-020-0671-6","article-title":"Cerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome","volume":"45","author":"Bindila","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fgene.2020.00125","article-title":"Association of a variant of CNR1 gene encoding cannabinoid receptor 1 with gilles de la Tourette syndrome","volume":"11","author":"Szejko","year":"2020","journal-title":"Front. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-023-09475-z","article-title":"Role of the endocannabinoid system in fragile X syndrome: Potential mechanisms for benefit from cannabidiol treatment","volume":"15","author":"Palumbo","year":"2023","journal-title":"J. Neurodev. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3389\/fncel.2018.00405","article-title":"Immune dysfunction and autoimmunity as pathological mechanisms in autism spectrum disorders","volume":"12","author":"Hughes","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"89","author":"Poleg","year":"2018","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","article-title":"Cannabidiol as a potential treatment for anxiety disorders","volume":"12","author":"Blessing","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1046\/j.1460-9568.1999.00847.x","article-title":"Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain","volume":"11","author":"Marsicano","year":"1999","journal-title":"Eur. J. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1137957","DOI":"10.3389\/fnbeh.2023.1137957","article-title":"Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation","volume":"17","author":"Kibret","year":"2023","journal-title":"Front. Behav. Neurosci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: A systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s10803-010-0996-9","article-title":"The heavy burden of psychiatric comorbidity in youth with autism spectrum disorders: A large comparative study of a psychiatrically referred population","volume":"40","author":"Joshi","year":"2010","journal-title":"J. Autism Dev. Disord."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/09540261.2018.1435513","article-title":"Treatment of severe problem behaviour in children with autism spectrum disorder and intellectual disabilities","volume":"30","author":"Newcomb","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1177\/1362361316689330","article-title":"Self-injurious behaviors in children with autism spectrum disorder enrolled in the study to explore early development","volume":"22","author":"Soke","year":"2018","journal-title":"Autism"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s10803-016-2946-7","article-title":"Psychotropic medication use among insured children with autism spectrum disorder","volume":"47","author":"Madden","year":"2017","journal-title":"J. Autism Dev. Disord."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems\u2014A Retrospective Feasibility Study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities","volume":"9","author":"Barchel","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s42238-021-00108-7","article-title":"CBD-enriched cannabis for autism spectrum disorder: An experience of a single center in Turkey and reviews of the literature","volume":"3","author":"Bilge","year":"2021","journal-title":"J. Cannabis Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched cannabis sativa extract on autism spectrum disorder symptoms: An observational study of 18 participants undergoing compassionate use","volume":"10","author":"Caixeta","year":"2019","journal-title":"Front. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: An open label study","volume":"12","author":"Hacohen","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy","volume":"9","author":"Mechoulam","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Silva Junior, E.A.d., Medeiros, W.M.B., Torro, N., Sousa, J.M.M.d., Almeida, I.B.C.M.d., Costa, F.B.d., Pontes, K.M., Nunes, E.L.G., Rosa, M.D.d., and Albuquerque, K.L.G.D.d. (2021). Cannabis and cannabinoid use in autism spectrum disorder: A systematic review. Trends Psychiatry Psychother.","DOI":"10.47626\/2237-6089-2020-0149"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: A proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schnapp, A., Harel, M., Cayam-Rand, D., Cassuto, H., Polyansky, L., and Aran, A. (2022). A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071685"},{"key":"ref_35","first-page":"36","article-title":"Medical marijuana: A Triumph of hope over experience","volume":"66","author":"Whitehall","year":"2022","journal-title":"Quadrant"},{"key":"ref_36","unstructured":"Thomas, M., and Frampton, C. (2022, December 22). HOPE\u00ae 1 Demonstrates Improvements in Clinical Global Impression (CGI) in Patients with Autism Spectrum Disorder. Available online: https:\/\/zeliratx.com\/wp-content\/uploads\/2022\/04\/ZEL040-White-Paper_Hope_FA.pdf."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/dmcn.14548","article-title":"Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: A randomized controlled trial","volume":"62","author":"Fairhurst","year":"2020","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_38","first-page":"264","article-title":"Longer-term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder: An Open-label Phase 2 Study (BRIGHT [ZYN2-CL-030])","volume":"149","author":"Palumbo","year":"2022","journal-title":"Pediatrics"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107878","DOI":"10.1016\/j.pharmthera.2021.107878","article-title":"Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder","volume":"226","author":"Zamberletti","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0074-7750(03)01002-4","article-title":"Psychopathology and intellectual disability: The Australian child to adult longitudinal study","volume":"26","author":"Tonge","year":"2003","journal-title":"Int. Rev. Res. Ment. Retard."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e017406","DOI":"10.1136\/bmjopen-2017-017406","article-title":"Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study","volume":"7","author":"Sheehan","year":"2017","journal-title":"BMJ Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00004703-200610000-00029","article-title":"An open label study of the use of dronabinol (Marinol) in the management of treatment-resistant self-injurious behavior in 10 retarded adolescent patients","volume":"27","author":"Kruger","year":"2006","journal-title":"J. Dev. Behav. Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e034362","DOI":"10.1136\/bmjopen-2019-034362","article-title":"Does cannabidiol reduce severe behavioural problems in children with intellectual disability? Study protocol for a pilot single-site phase I\/II randomised placebo controlled trial","volume":"10","author":"Efron","year":"2020","journal-title":"BMJ Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J. Neurodev. Disord."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","article-title":"A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)","volume":"14","author":"Hagerman","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ije\/dyt261","article-title":"ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis","volume":"43","author":"Polanczyk","year":"2014","journal-title":"Int. J. Epidemiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.acap.2013.03.009","article-title":"Current Australian pediatric practice in the assessment and treatment of ADHD","volume":"13","author":"Efron","year":"2013","journal-title":"Acad. Pediatr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaac.2013.09.001","article-title":"Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit\/hyperactivity disorder: United States, 2003\u20132011","volume":"53","author":"Visser","year":"2014","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1056\/NEJMcp032387","article-title":"Attention Deficit\u2013Hyperactivity Disorder","volume":"352","author":"Rappley","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1440-1754.2005.00530.x","article-title":"Complementary and alternative medicine use in children with attention deficit hyperactivity disorder","volume":"41","author":"Sinha","year":"2005","journal-title":"J. Paediatr. Child Health"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jpsychires.2022.11.029","article-title":"Cannabis use in attention\u2013Deficit\/hyperactivity disorder (ADHD): A scoping review","volume":"157","author":"Francisco","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.cpr.2011.01.006","article-title":"Prospective association of childhood attention-deficit\/hyperactivity disorder (ADHD) and substance use and abuse\/dependence: A meta-analytic review","volume":"31","author":"Lee","year":"2011","journal-title":"Clin. Psychol. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Mitchell, J.T., Sweitzer, M.M., Tunno, A.M., Kollins, S.H., and McClernon, F.J. (2016). \u201cI use weed for my ADHD\u201d: A qualitative analysis of online forum discussions on cannabis use and ADHD. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156614"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/10870547211050949","article-title":"Self-reported effects of cannabis on ADHD symptoms, ADHD medication side effects, and ADHD-related executive dysfunction","volume":"26","author":"Stueber","year":"2022","journal-title":"J. Atten. Disord."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","article-title":"Cannabinoids in attention-deficit\/hyperactivity disorder: A randomised-controlled trial","volume":"27","author":"Cooper","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e31281","DOI":"10.2196\/31281","article-title":"Pharmacokinetics and Perceptions of Children and Young Adults Using Cannabis for Attention-Deficit\/Hyperactivity Disorder and Oppositional Defiant Disorder: Protocol for a Mixed Methods Proof-of-Concept Study","volume":"10","author":"Mansell","year":"2021","journal-title":"JMIR Res. Protoc."},{"key":"ref_57","unstructured":"Therapeutic Goods Administration Department of Health and Aged Care Australian Government (2023, January 31). Medicinal Cannabis Special Access Scheme Category B Data, Available online: https:\/\/www.tga.gov.au\/products\/unapproved-therapeutic-goods\/medicinal-cannabis-hub\/medicinal-cannabis-access-pathways-and-patient-access-data\/medicinal-cannabis-special-access-scheme-category-b-data."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/02698811211032445","article-title":"Pharmacological treatment for Tourette syndrome in children and adults: What is the quality of the evidence? A systematic review","volume":"35","author":"Besag","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/JCP.0b013e3181d236ec","article-title":"Oral \u03949-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: A case report","volume":"30","author":"Hasan","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Jakubovski, E., and M\u00fcller-Vahl, K. (2017). Speechlessness in Gilles de la Tourette syndrome: Cannabis-based medicines improve severe vocal blocking tics in two patients. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081739"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.24911\/ejmcr\/2\/11","article-title":"Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome: Case report","volume":"2","author":"Szejko","year":"2018","journal-title":"Eur. J. Med. Case Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1159\/000496355","article-title":"Vaporized cannabis is effective and well-tolerated in an adolescent with Tourette syndrome","volume":"2","author":"Szejko","year":"2019","journal-title":"Med. Cannabis Cannabinoids"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","article-title":"Treatment of Tourette's syndrome with \u03949-tetrahydrocannabinol (THC): A randomized crossover trial","volume":"35","author":"Schneider","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Abi-Jaoude, E., Bhikram, T., Parveen, F., Levenbach, J., Lafreniere-Roula, M., and Sandor, P. (2022). A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome. Cannabis Cannabinoid Res.","DOI":"10.1089\/can.2022.0091"},{"key":"ref_65","first-page":"4111","article-title":"Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial","volume":"64","author":"Schneider","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Sarris, J., Sinclair, J., Karamacoska, D., Davidson, M., and Firth, J. (2020). Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review. BMC Psychiatry, 20.","DOI":"10.1186\/s12888-019-2409-8"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.3389\/fpsyg.2019.02466","article-title":"Anxiolytic effects of repeated cannabidiol treatment in teenagers with social anxiety disorders","volume":"10","author":"Masataka","year":"2019","journal-title":"Front. Psychol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"42111","DOI":"10.4088\/JCP.21m14130","article-title":"Cannabidiol for treatment-resistant anxiety disorders in young people: An open-label trial","volume":"83","author":"Berger","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","article-title":"Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: A randomized clinical trial","volume":"75","author":"Bhattacharyya","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/eip.13182","article-title":"Cannabidiol for at risk for psychosis youth: A randomized controlled trial","volume":"16","author":"Amminger","year":"2022","journal-title":"Early Interv. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/can.2016.0034","article-title":"An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies","volume":"2","author":"Iffland","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"586110","DOI":"10.3389\/fphar.2020.586110","article-title":"Cannabidiol treatment for refractory epilepsies in pediatrics","volume":"11","author":"Raucci","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1073\/pnas.1516648113","article-title":"Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies","volume":"113","author":"Jackson","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"10154","DOI":"10.1038\/s41598-018-28127-0","article-title":"Composition and use of cannabis extracts for childhood epilepsy in the Australian community","volume":"8","author":"Suraev","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.2015.6613","article-title":"Cannabinoid dose and label accuracy in edible medical cannabis products","volume":"313","author":"Vandrey","year":"2015","journal-title":"JAMA"},{"key":"ref_77","unstructured":"C.S. Mott Children\u2019s Hospital (2023, February 08). National Poll on Children\u2019s Health: Parent Perspectives on CBD Use in Children. Available online: https:\/\/mottpoll.org\/sites\/default\/files\/documents\/022122_CBD.pdf."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"101994","DOI":"10.1016\/j.rasd.2022.101994","article-title":"A natural history study of medical cannabis consumption in pediatric autism in the United States","volume":"96","author":"DiLiberto","year":"2022","journal-title":"Res. Autism Spectr. Disord."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1186\/s13063-020-04862-6","article-title":"Clinical trials with cannabis medicines\u2014Guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: Considerations from the Australian experience","volume":"21","author":"Martin","year":"2020","journal-title":"Trials"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e20171818","DOI":"10.1542\/peds.2017-1818","article-title":"Medical cannabinoids in children and adolescents: A systematic review","volume":"140","author":"Wong","year":"2017","journal-title":"Pediatrics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5694\/mja17.01004","article-title":"Compassion and evidence in prescribing cannabinoids: A perspective from the Royal Australasian College of Physicians","volume":"208","author":"Martin","year":"2018","journal-title":"Med. J. Aust."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/8\/5430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:11:49Z","timestamp":1760123509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/20\/8\/5430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijerph20085430"],"URL":"https:\/\/doi.org\/10.3390\/ijerph20085430","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}